BioSpace News Archive

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported first quarter financial results for the period ended March 31, 2023 and provided an update on recent company developments.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Ron Renaud as president and chief executive officer, and member of the company’s board of directors, effective June 12, 2023.

Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2023.

Centene Corporation announced that it has signed a definitive agreement to sell Apixio, a leading artificial intelligence platform that enables value-based care, to New Mountain Capital, a growth-oriented investment firm with more than $37 billion in assets under management.

Sage Therapeutics, Inc. announced that the Company will present at the following upcoming investor conferences in May: BofA Securities 2023 Health Care Conference : presentation on Wednesday, May 10, 2023 at 2:20 p.m. PT.

ImmunoGen Inc. (Nasdaq: IMGN) today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.

ADMA Biologics, Inc. today announced that it will report first quarter 2023 financial results on May 10, 2023, after the U.S. financial markets close.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that members of Management will participate in three upcoming conferences.

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET on Wednesday, May 10, 2023.

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.